Minerva Neurosciences, Inc.
NERV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001598646
No open-market purchases or sales by Minerva Neurosciences, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $234.8M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Minerva Neurosciences, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 46 | 35 | −11 |
| Shares | 24.7M | 20.7M | −3.93M (−15.9%) |
| Value | $42.9M | $16.6M | −$26.3M (−61.3%) |
New holders (3)
Institutions that held Minerva Neurosciences, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 10,923 | $9.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 8,046 | $6.00K | 0.00% |
| Aquatic Capital Management LLC | 2,200 | $2.00K | 0.00% |
Sold out (14)
Institutions that held Minerva Neurosciences, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Assenagon Asset Management S.A. | 1,082,333 | $1.88M |
| Jacobs Levy Equity Management, Inc | 487,140 | $848.0K |
| Gsa Capital Partners LLP | 480,629 | $836.0K |
| Highland Capital Management Fund Advisors, L.P. | 400,000 | $696.0K |
| Connor, Clark & Lunn Investment Management Ltd. | 143,761 | $250.0K |
| Cormorant Asset Management, LP | 95,744 | $167.0K |
| Price T Rowe Associates Inc | 56,300 | $98.0K |
| Rafferty Asset Management, LLC | 48,865 | $85.0K |
| ExodusPoint Capital Management, LP | 39,190 | $68.0K |
| Palo Alto Investors LP | 36,319 | $63.0K |
| Goldman Sachs Group Inc | 33,559 | $58.0K |
| JPMorgan Chase & Co | 17,295 | $30.0K |
| Two Sigma Securities, LLC | 16,788 | $29.0K |
| Barclays PLC | 5,045 | $9.00K |